Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Medexus Pharmaceuticals Inc ( (TSE:MDP) ).
Medexus Pharmaceuticals announced the FDA approval of GRAFAPEX (treosulfan) for injection, a significant development in hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome. The approval is expected to strengthen Medexus’s market position in the U.S., with projections of annual revenue exceeding $100 million within five years post-launch, and it will provide a new treatment option that could improve patient outcomes.
More about Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on developing and commercializing innovative therapeutic products. The company holds a significant market position with a focus on products that address specialized medical needs, particularly in the fields of hematology and oncology.
YTD Price Performance: 15.65%
Average Trading Volume: 45,601
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$98.36M
For detailed information about MDP stock, go to TipRanks’ Stock Analysis page.
